<DOC>
	<DOCNO>NCT00450801</DOCNO>
	<brief_summary>RATIONALE : To evaluate efficacy new high intensity chemotherapy regimen thalidomide maintenance patient newly diagnose mantle cell lymphoma PURPOSE : This phase II trial study well give rituximab together combination chemotherapy follow thalidomide work treat patient previously untreated mantle cell lymphoma .</brief_summary>
	<brief_title>R-MACLO-IVAM Thalidomide Untreated Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine progression-free survival patient previously untreated mantle cell lymphoma treat rituximab combination methotrexate , doxorubicin , cyclophosphamide , leucovorin , vincristine , ifosfamide , etoposide , cytarabine mesna ( MACLO/IVAM ) follow thalidomide . Secondary - Determine overall survival patient treat regimen . - Determine response rate patient treat regimen . - Determine toxicity regimen patient . OUTLINE : During cycle 1 , patient receive rituximab intravenous ( IV ) , granisetron IV , decadron IV , doxorubicin IV bolus , vincristine intravenous pyelogram ( IVP ) day 1 ; cyclophosphamide IV day 1-5 ; vincristine IVP day 8 ; methotrexate IV , methotrexate continuous infusion , leucovorin IV methotrexate level 0.01 nanomolar ( nM ) day 10 . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 13 continue blood count recover . When absolute neutrophil count ( ANC ) reaches1,500/mm^3 , patient start cycle 2 . Patients receive rituximab IV day 1 ; cytarabine IV day 1 2 ; ifosfamide IV , mesna IV , etoposide IV day 1-5 ; G-CSF SC daily begin day 7 continue ANC great 1,000 cells/mm^3 . Approximately 2-3 week later , patient receive another course therapy above.After cycle 4 , patient complete remission take oral thalidomide progression disease . After completion study treatment , patient follow monthly 3 month , every 3 month 2 year , every 6 month 3-5 year , annually thereafter study termination . PROJECTED ACCRUAL : A total 22 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>Previously untreated , histologically confirm mantle cell lymphoma . Measurable evaluable disease . All stage eligible . Age &gt; 18 year . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Adequate hepatic function : Bilirubin &lt; 3 mg/dL . Transaminases ( SGOT and/or SGPT ) &lt; 2.5 time upper limit normal institution , unless due lymphomatous involvement . Serum creatinine &lt; 1.5 mg/Dl . Ability give inform consent . Women childbearing potential must negative pregnancy test within 72 hour enter study . Males females must agree use adequate birth control conception possible study . Women must avoid pregnancy men avoid father child study . Life expectancy great 6 month . Previous chemotherapy , immunotherapy radiotherapy lymphoma Concurrent active malignancy , exception situ carcinoma cervix basal cell carcinoma skin . Grade 3 4 cardiac failure and/or ejection fraction &lt; 50 . Psychological , familial , sociological geographical condition permit treatment and/or medical followup require comply study protocol . Patients known history HIV AIDS Presence hepatitis hepatitis B virus ( HBV ) infection Pregnant breastfeeding woman . Central nervous system ( CNS ) involvement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>